Kevin Waweru Mwangi

PhD Student

Ghent University - PROVAXS

GENT, Belgium

2 profile visits

I’m a PhD student working on mRNA-based lipid nanoparticle (LNP) vaccines for lung cancer. Focus on harnessing these platforms to immunomodulate the TME.

My organisation

Ghent University - PROVAXS

Ghent University - PROVAXS

Academic institution

Merelbeke, Belgium

Provaxs is Ghent University’s Business Development Center and industrial liaison for innovation in animal health. We combine scientific expertise, knowledge and know-how on animal health with an entrepreneurial organisation of scientists and experienced tech-transfer professionals. Not only that, but thanks to the Industrial Research Fund of Ghent University we have access to proof-of-concept funding, open for collaboration with industry. We are receptive to all types of collaborations and partnerships:  out-licensing and development of our UGent-technologies towards the final product, research collaboration on a single project, either bilateral or in a research consortium, strategic partnerships with a specific focus/topic.  All our collaborations and partnerships are supported by a professional business development/tech-transfer team and are based on solid tailor-made agreements on confidentiality, ownership, and exploitation of results.
Read more

About me

I am a PhD student investigating mRNA-based lipid nanoparticle (LNP) vaccines for lung cancer immunotherapy. My research focuses on using the Galsome platform to deliver mRNA to specific subsets of dendritic cells (DCs), aiming to prime cytotoxic T cells and induce broader immune responses. We are particularly interested in how this targeted activation can also generate bystander effects on unconventional T cell populations. Using the Lewis lung carcinoma (LLC) mouse model, I explore how this approach can reshape the tumor microenvironment and improve anti-tumor efficacy in non-small cell lung cancer.

Social media